Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity

Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuropharmacology
Asıl Yazarlar: De Bellis, Michela, Carbonara, Roberta, Roussel, Julien, Farinato, Alessandro, Massari, Ada, Pierno, Sabata, Muraglia, Marilena, Corbo, Filomena, Franchini, Carlo, Carratù, Maria Rosaria, De Luca, Annamaria, Conte Camerino, Diana, Desaphy, Jean-François
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Pergamon Press 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5154332/
https://ncbi.nlm.nih.gov/pubmed/27743929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2016.10.013
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller